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AbstrAct
Lymph node expansion during inflammation is essential to establish immune 
responses and relies on the development of blood and lymph vessels. Previous 
work in mice has shown that this process depends on the presence of VEGF-A 
produced by B cells, macrophages and stromal cells. In humans, however, the cell 
types and the mechanisms regulating the intranodal production of VEGF-A remain 
elusive. Here we show that CD11c+ cells represent the main VEGF-A-producing cell 
population in human reactive secondary lymphoid organs. In addition we find that 
three transcription factors, namely CREB, HIF-1α and STAT3, regulate the expression 
of VEGF-A in inflamed DCs. Both HIF-1α and STAT3 are activated by inflammatory 
agonists. Conversely, CREB phosphorylation represents the critical contribution of 
endogenous or exogenous PGE2. Taken together, these results propose a crucial role 
for DCs in lymph node inflammatory angiogenesis and identify novel potential cellular 
and molecular targets to limit inflammation in chronic diseases and tumors. 
IntroductIon
VEGF-A is a potent pro-angiogenic mediator 
typically released under hypoxic conditions, but is also 
a hallmark of inflammation [1-3]. The regulation of 
VEGF-A secretion by hypoxia has been thoroughly 
characterized (reviewed in [4, 5]). Far less is known about 
its regulation by pro-inflammatory stimuli, although 
transcription seems to play a predominant role [5]. 
The VEGF-A promoter spans more than 2 kb upstream 
of the transcription start site [6] and comprises many 
phylogenetically conserved binding sites for transcription 
factors such as HIF-1α, STAT3, CREB, nuclear receptors 
and Sp1 [5]. Among these, HIF-1α is recognized as the 
master regulator of VEGF-A transcription, although it is 
now clear that other transcription factors are required to 
support its key function [7].
During inflammation, draining lymph nodes rapidly 
enlarge and increase in cellularity to foster the encounter 
between antigens and immune cells. Lymph node swelling 
is supported by a dramatic increase in blood vasculature 
to provide oxygen, nutrient and immune cell delivery [8] 
and by robust lymphangiogenesis that further enhances 
the possibilities of DC-T lymphocyte interactions [9] 
[10]. The mechanisms regulating the growth of blood and 
lymphatic vasculature in lymph nodes are not completely 
understood, but several studies point to a pivotal role for 
VEGF-A [11] [12] [13]. The intranodal source of VEGF-A 
has been investigated in the mouse system and comprises 
follicular B cells [14, 15], CD11b+ macrophages [16, 
17] and reticular stromal cells [18]. Also CD11c+ DCs 
were suggested to have an indirect role in the increase of 
intranodal VEGF-A [13]. In humans, the cellular source 
of VEGF-A in inflamed lymph nodes remains completely 
elusive [19]. 
DCs are antigen presenting cells located at the 
interface between innate and adaptive immunity. DCs 
express a vast repertoire of pattern recognition receptors 
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and the binding of pathogen- and damage-associated 
molecular patterns (PAMPs and DAMPs) activates a 
complex pro-inflammatory program that contributes to 
the local inflammatory response [20]. After antigen uptake 
in peripheral tissues, DCs travel via afferent lymphatics 
to the draining lymph nodes where they activate antigen-
specific T lymphocytes [21]. 
We have previously reported that human monocyte-
derived DCs represent an important source of biologically 
active VEGF-A
165
 and VEGF-A
121
 [22]. This work 
investigates the ability of DCs to produce VEGF-A 
in human activated lymph nodes and characterizes 
the molecular mechanisms responsible for VEGF-A 
transcription under inflammatory conditions. 
results
cd11c+ cells produce VEGF-A in human inflamed 
secondary lymphoid organs
Staining of reactive tonsils and lymph nodes, 
including tumor-draining lymph nodes, with an anti-
VEGF-A antibody revealed a strong intracytoplasmic 
granular reactivity surrounding CD31+ high endothelial 
venules (HEVs) (Figure 1A). These VEGF-A+ cells 
represented a fraction of CD11c+ cells in both lymph 
nodes (Figure 1B) and tonsils (Figure 1C), whereas pDCs, 
B and T lymphocytes were negative (Supplemental Figure 
Figure 1: distribution and phenotype of VeGF-A-producing cells in human reactive lymphoid tissues. A. In reactive 
lymph nodes, VEGF-A+ cells surround CD31+ HEVs and b. co-express CD11c. c. In tonsils, strong cytoplasmic signal for VEGF-A is 
observed in CD11c+ cells in the interfollicular area (red arrow head) and CD11c+ germinal centre macrophages (black arrow head). d. 
Cytospin preparation of CD1c+ DCs sorted from tonsils shows VEGF-A-reactivity. e. In dermatopathic lymphadenitis, strong cytoplasmic 
VEGF-A is clearly detected in CD1a+ and CD207+ (inset) interdigitating DCs. Sections are from FFPE reactive lymph nodes (A., b., e.) and 
tonsil (C). Stainings are indicated by labels. Representative double positive cells in each panel are indicated by arrow heads and detailed at 
a high power view insets. Sections are counterstained with Meyer’s haematoxylin. Original magnifications: 200X (A., scale bar 100 μm), 
400X (b., c., e. scale bar 50 μm), 600X (d. and insets, scale bar 33 μm).
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1A, B and C). CD11c+ cells comprise both macrophages 
and myeloid DCs (mDCs), the latter being identified 
as CD1c+. Since an anti-CD1c antibody working on 
formalin-fixed tissue sections is currently not available, 
the expression of VEGF-A by mDCs was confirmed in 
CD1c+ mDCs freshly purified from human tonsils (Figure 
1D). Of note, as reported in previous studies, CD1c+ 
cells represent the majority of HLADR+CD11c+ cells in 
reactive tonsils and lymph nodes (data not shown) [23, 
24]. In addition to mDCs, VEGF-A reactivity was detected 
in CD1a+ and CD207+ interdigitating DCs (Figure 1E and 
inset, respectively and in some CD163+ macrophages 
(Supplemental Figure 1D). In reactive tonsils, a minor 
fraction of M-DC8/DD1+ slanDCs costained for VEGF-A 
(Supplemental Figure 1E).
Collectively, these data indicate that myeloid DC 
subsets, interdigitating DCs of Langerhans cell derivation 
and macrophages represent a major source of VEGF-A in 
human inflamed secondary lymphoid organs.
the release of VeGF-A induced by pro-
inflammatory stimuli depends on the presence of 
PGe2
The ability of DCs to produce VEGF-A in 
response to different pro-inflammatory mediators was 
further investigated in vitro. Monocyte-derived DCs 
were stimulated with Toll Like Receptor-(TLR) ligands 
(Figure 2A), or whole bacteria (Staphilococcus aureus, 
Escherichia coli), C-type lectin ligands (β-glucan, Curdlan 
and Candida albicans), pro-inflammatory cytokines (IL-
1β and TNF-α) and necrotic cell-associated DAMPs 
(Figure 2B). Among these, only the ligands for TLR4 and 
TLR7-8, necrotic cell-associated DAMPs and, although at 
a low extent, β-glucan induced the release of VEGF-A. On 
the other hand, all stimuli became active in the presence 
of PGE
2
, the predominant eicosanoid produced in inflamed 
tissues and growing tumors [25]. Of note, PGE
2
 by itself 
did not induce VEGF-A (Figure 2A and 2B). According 
to the results obtained in tissue section, similar inductions 
were also obtained with in vitro differentiated Langerhans 
cells (Figure 2C) and primary mDCs (Figure 2D). Also, 
blood purified pDCs did not produce VEGF-A under 
basal conditions or when stimulated with TLR7- or TLR9-
ligands either in the presence or absence of PGE
2
 (Figure 
2D).
Since LPS induces PGE
2
 synthesis [26], a role for 
endogenous PGE
2
 in inflammatory VEGF-A production 
was postulated. In accordance with this hypothesis, we 
found a clear correspondence between the capability 
to induce endogenous PGE
2
 and VEGF-A production 
(Figure 3A). Furthermore, the production of both 
mediators was ihibited by U0126, PD98059, SB203580 
and BAY11-7082 (inhibitors of mitogen-activated protein 
kinase kinases, extracellular-signal-regulated kinase 1/2 
(ERK1/2), MAPK p38 and NF-κB respectively), but 
not by the JNK inhibitor II (Figure 3B), suggesting the 
regulation by a common signalling pathways. Similar 
results were obtained with R848-stimulated DCs (data 
not shown). The role of endogenous PGE
2
 in VEGF-A 
secretion was further substantiated by two experimental 
approaches. First, by using specific inhibitors for two 
enzymes located upstream of PGE
2
 production, namely 
phospholipase A
2
 (PLA
2
) and COXs. Figure 3C shows 
that AACOF3 (a calcium-dependent PLA
2
 inhibitor), as 
well as indomethacin (a pan-COX-1/2 inhibitor), inhibited 
in a concentration-dependent manner VEGF-A production 
in LPS-stimulated DCs. As expected, both inhibitors 
also abolished the release of endogenous PGE
2
 (data 
not shown). We found that DCs express basal levels of 
Prostaglandin E receptor 2 and 4 (EP
2
 and EP
4
) that are not 
modulated by LPS stimulation (Supplemental Figure 2A). 
These receptors are functional and mediate DC response to 
PGE
2
, because Butaprost (an EP
2
 agonist) and Misoprostol 
(a promiscuous EP
2-4
 agonist) recapitulated PGE
2
 effects 
in LPS-stimulated DCs (Supplemental Figure 2B). Thus, 
as a second approach, cell activation by autocrine PGE
2
 
was blocked by the use of specific inhibitors of EP
2 
and 
EP
4
. Figure 3C shows that AH 6809+GW 627368X (EP
2
 
and EP
4
 antagonists, respectively) decreased VEGF-A 
production in a concentration-dependent manner.
Therefore, the ability of TLR-ligands to induce 
VEGF-A secretion directly correlates with the ability 
to activate PGE
2
 synthesis. This autocrine mechanism 
is supported by in vivo observations documenting 
the colocalization of anti-VEGF-A and anti-PGE
2
 
immunoreactivity in CD11c+ cells (Figure 3D). 
Inflammatory VEGF-A transcription requires the 
coordinated activation of multiple transcription 
factors
These results prompted us to investigate the 
molecular mechanisms involved in the combined 
activation of DCs by TLR ligands and PGE
2
. Studies 
were focused on the combination Poly I:C+PGE
2
 as the 
paradigm of a positive interaction of two agonists that 
are by themself inactive in VEGF-A production, while 
LPS was selected as the prototypic active agonist. The 
induction of VEGF-A mRNA was largely dependent on the 
activation of gene transcription, as shown by the use of the 
RNA polymerase II (RNApolII) inhibitor 5,6-Dichloro-
1-β-D-ribofuranosylbenzimidazole (DRB), which dose-
dependently decreased the peak levels of VEGF-A mRNA 
(Figure 4A) and by RNApolII recruitment to the VEGF-A 
promoter by chromatin immunoprecipitation (ChIP) 
(Figure 4B). 
Since PGE
2 
by itself does not induce VEGF-A 
production, it is likely to contribute to the activation of 
a transcription factor that is crucial, but not sufficient 
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Figure 2: Human myeloid DCs produce VEGF-A in response to a variety of pro-inflammatory stimuli, provided PGE2 
is present in the microenvironment. A., b. DCs were stimulated for 24 hours with TLR-ligands PAM
3
CSK
4
 (TLR1/2, 100 ng/ml), 
FSL-1 (TLR2/6, 100 ng/ml), Poly I:C (TLR3, 25 µg/ml), LPS (TLR4, 100 ng/ml) and R848 (TLR7 and TLR8, 5 µg/ml), Heat-killed 
S.aureus (specific for TLR2; 1:10 DC/bacteria ratio), E. coli (specific for TLR4; 1:10 DC/bacteria ratio), β-glucan (10 µg/ml), Curdlan (10 
µg/ml), heat-killed C.albicans (specific for C-type lectins; 1:10 DC/fungi ratio), IL-1β (20 ng/ml), TNF-α (20 ng/ml), and necrotic cells 
(1:2  DC/necrotic cells ratio) in the presence or absence of PGE
2 
(10 µM). VEGF-A production was evaluated in cell-free supernatants by 
ELISA. Data are expressed as mean + SEM (n = 4); * p < 0.05 by one-way ANOVA with Dunnet’s post hoc test. c. Langerhans cells (LCs) 
were stimulated for 24 hours with PAM
3
CSK
4
 (100 ng/ml), LPS (100 ng/ml), R848 (5 µg/ml), heat-killed C. albicans (1:10 DC/fungi ratio), 
IL-1β (20 ng/ml), TNF-α (20 ng/ml), and necrotic cells (1:2 DC/necrotic cells ratio) in the presence of 10 µM PGE
2
. VEGF-A production 
was evaluated by ELISA. Data are expressed as mean + SEM (n = 3). * p < 0.05 by one-way ANOVA with Dunnet’s post hoc test d. Blood 
purified mDCs and pDCs were stimulated as indicated for 24 hours and VEGF-A levels were analyzed by ELISA. Data are expressed as 
mean + SEM (n = 3); * p < 0.05 by Student’s t test; N.D. = Not Detectable.
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per se, for the inflammatory production of VEGF-A. 
HIF-1α, STAT3 and CREB were selected for further 
analysis among the transcription factors able to bind 
the VEGF-A promoter [5] and known to be activated 
by TLRs and PGE
2
. Poly I:C and LPS, but not PGE
2
, 
induced the nuclear accumulation of HIF-1α as well as 
the phosphorylation and nuclear translocation of STAT3 
(Figure 4C, upper panels). By contrast, PGE
2
 induced the 
rapid phosphorylation of CREB (Figure 4C, lower panels). 
Of note LPS, the only tested agonist with the ability to 
induce VEGF-A directly, also induced the phosphorylation 
of CREB, suggesting that only the concomitant presence of 
these three transcription factors can promote the activation 
of VEGF-A transcription. According to this hypothesis, 
Figure 3: tlr-4-dependent expression of VeGF-A depends on endogenous PGe2 production. A. DCs were stimulated 
with PAM
3
CSK
4
 (100 ng/ml), FSL-1 (100 ng/ml), Poly I:C (25 µg/ml), LPS (100 ng/ml) and R848 (5 µg/ml) for 24 hours. The production 
of VEGF-A and PGE
2
 was evaluated in cell-free supernatants by ELISA or EIA, respectively. Results are expressed as mean + SEM (n 
= 4); *p < 0.05 by one-way ANOVA with Dunnet’s post hoc test. b. DCs were pre-treated for 1 hour with U0126 (1 µM), PD98059 (PD, 
1 µM), SB203580 (SB, 1 µM), JNK Inhibitor II (JNK, 1 µM), BAY-11-7082 (BAY, 1 µM) and then stimulated with LPS (100 ng/ml) for 
24 hours. VEGF-A and PGE
2 
production was evaluated by ELISA or EIA, respectively. Results are expressed as mean + SEM (n = 3); *p 
< 0.05 by one-way ANOVA with Dunnet’s post hoc test. c. DCs were pre-treated for 1 hour with increasing concentrations of AACOF3 
(cPLA
2
 inhibitor, grey circles), indomethacin (a non-selective COX-1/COX-2 inhibitor, black circles) or AH 6809+GW 627368X (EP
2
 and 
EP
4
 antagonist respectively, open circles) and then stimulated with LPS. After 24 hours, supernatants were collected and the production of 
VEGF-A evaluated by ELISA. Data are expressed as mean + SEM (n = 3); *p < 0.05 by one-way ANOVA with Dunnet’s post hoc test. d. In 
reactive lymph nodes, a fraction of CD11c+ cells costains for VEGF-A and PGE
2
. Sections are counterstained with Meyer’s haematoxylin. 
Original magnification: 600X (scale bar 33 μm). 
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Figure 4: The pro-inflammatory VEGF-A transcription correlates with the activation of HIF-1α, STAT3 and CREB. 
A. DCs were pre-treated with increasing concentrations of RNApolII inhibitor DRB for 30 minutes and then stimulated with LPS (6 
hours), LPS+PGE
2
 or Poly I:C+PGE
2 
(3 hours). VEGF-A mRNA levels were evaluated by real-time PCR. Data are presented as mean 
+ SEM (n = 3) of percentage of induction (100% indicates peak mRNA levels for each individual stimulus); *p < 0.05 by one-way 
ANOVA with Dunnet’s post hoc test. b. DCs were stimulated with LPS, LPS+PGE
2
 or Poly I:C+PGE
2 
for the indicated time-points. 
Sonicated nuclear fractions were subjected to ChIP with anti-RNApolII (PolII) antibody and analyzed by RT-PCR. Data are shown as the 
immunoprecipitated percentage of input DNA and are expressed as mean + SEM (n = 3); * p < 0.05 compared with respective controls by 
one-way ANOVA with Dunnet’s post hoc test. c., e. DCs were stimulated with 10 µM PGE
2
, 25 µg/ml Poly I:C and 100 ng/ml LPS for 
6 hours (c., upper panels) or 30 minutes (c., lower panels) or Poly I:C+PGE
2
 or LPS+PGE
2
 for 3 hours (e) and blotted against HIF-1α, 
phospho-STAT3 or phospho-CREB. Lamin B represents the loading control for nuclear proteins. One representative fluorogram out of 
three and its densitometric analysis are shown. The time points shown in the figure represent the peak intensity of kinetic stimulations of 
30 minutes, 1, 3, 6 and 8 hours. One representative experiment out of 3 is shown. d. (upper panel) DCs were pre-treated for 1 hour with 5 
µM H89 (PKA inhibitor, striped bar) or 3 µM CBP-CREB interaction inhibitor (black bar) and stimulated with LPS for 24 hours. VEGF-A 
production was evaluated by ELISA. Results are expressed as mean + SEM (n = 3); *p < 0.05 by one-way ANOVA with Dunnet’s post 
hoc test. (d., lower panel) DCs were pre-treated for 30 minutes with 100 nM indomethacin and then stimulated with LPS. Nuclear extracts 
were blotted against phospho-CREB. Lamin B represents the loading control for nuclear proteins. One representative fluorogram out of 
three and its densitometric analysis are shown. F. Nuclear fractions of DCs stimulated with Poly I:C+PGE
2
 for 3 hours were subjected to 
chromatin immunoprecipitation with antibodies directed against HIF-1α, phospho-CREB and STAT3. Data are shown as percentage of 
immunoprecipitated DNA and are expressed as mean + SEM (n = 3); * p < 0.05 by Student’s t test. 
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both a specific CREB inhibitor and H89, an inhibitor 
of the CREB-phosphorylating enzyme PKA, strongly 
reduced the secretion of VEGF-A in LPS-stimulated DCs 
(Figure 4D, upper panel). Also, indomethacin reduced 
the LPS-dependent phosphorylation of CREB, thus 
demonstrating that endogenous PGE
2
 is responsible for 
CREB phosphorylation (Figure 4D, lower panel). Of note, 
the combined stimulation of DCs with Poly I:C+PGE
2
 
induced the concomitant nuclear translocation of all 
transcription factors (Figure 4E) and their recruitment to 
the VEGF-A promoter (Figure 4F). Similar results were 
obtained in LPS+PGE
2
-stimulated DCs (Figure 4E and 
Figure 5: The pro-inflammatory secretion of VEGF-A requires the concomitant activation of HIF-1α, STAT3 and 
creb. A.-c. DCs were pre-treated for 1 hour with Chetomin, NSC 74859 or CBP-CREB inhibitor and stimulated with Poly I:C+PGE
2
 for 
24 hours. The release of VEGF-A  (A) or IL-6 (c) was evaluated by ELISA. Cell viability was evaluated by Propidium Iodide staining (b). 
d. DCs were stimulated with 400 µM CoCl
2
, 25 µM cpt-cAMP alone or in combination and in hypoxic conditions (Hyp) in the presence or 
absence of 10 µM PGE
2
 for 24 hours. The production of VEGF-A was evaluated by ELISA in cell free supernatants. Results are expressed 
as mean + SEM (n = 3). * p < 0.05 compared to respective controls by Student’s t test or one-way ANOVA with Dunnet’s post hoc test as 
appropriate. (d., left inset) DCs were stimulated with 400 µM CoCl
2 
for 4 hours or (d., right inset) with 25 µM cpt-cAMP for 30 minutes 
and blotted against HIF-1α, phospho-STAT3 or phospho-CREB. Lamin B represents the loading control for nuclear proteins.
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Supplemental Figure 3A). 
The requirement of these three transcription 
factors for VEGF-A production was further confirmed 
by the use of specific inhibitors. Figure 5A shows that 
Chetomin (an inhibitor of the interaction of HIF-1α with 
transcriptional co-activators p300 and CBP), NSC 74859 
(a STAT3 inhibitor) and CBP-CREB (a CREB inhibitor) 
dose-dependently reduced the secretion of VEGF-A 
after Poly I:C+PGE
2 
stimulation. Although with the 
highest concentrations of the first two inhibitors a minor 
reduction in cell viability was observed at the end of 
24 hour-stimulation (Figure 5B), the ability of the cells 
to release IL-6, an unrelated cytokine, was not affected 
(Figure 5C). These results strongly suggest that the 
inhibition of VEGF-A production was not due to the toxic 
effects of the inhibitors. Similar results were obtained in 
LPS+PGE
2
-stimulated DCs (Supplemental Figure 3B-3D). 
Finally, the involvement of multiple transcription factors 
in VEGF-A induction was further strengthened by the use 
of chemical activators. Figure 5D shows that, in human 
DCs, CoCl
2
 (a drug activating HIF-1α and STAT3, left 
inset [27]) or hypoxia, were by themselves inactive and 
induced VEGF-A only when combined with the CREB-
phosphorylating agonist (8-(4-Chlorophenylthio)-cAMP 
(cpt-cAMP), or PGE
2
. 
These results indicate that the transcriptional 
activation of VEGF-A in inflamed DCs requires the 
concomitant activation of multiple transcription factors, 
namely CREB, HIF-1α and STAT3, and that CREB 
phosphorylation represents the crucial contribution of 
PGE
2
 to TLR-dependent VEGF-A secretion. 
dIscussIon
Activated DCs produce large amounts of 
chemokines, cytokines and oxygen radicals and represent 
an important component of the inflammatory reaction [21]. 
In adults, angiogenesis occurs mostly under pathological 
conditions, including inflammation. Newly formed blood 
vessels provide nutrients to growing tissues and allow 
Figure 6: Proposed model for inflammatory VEGF-A production. The triggering of TLR4 (or TLR7-8) induces the release of 
endogenous PGE
2
 (grey circle) which acts autocrinally on EP
2
 and/or EP
4
 receptors inducing robust CREB phosphorylation. This, together 
with TLR-activated HIF-1α and STAT3, finally induces VEGF-A transcription. For pattern recognition receptors that don’t release PGE
2
, 
exogenous PGE
2
 (black circle) provides CREB phosphorylation.
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accumulation of immune cells, both in peripheral tissues 
and in secondary lymphoid organs [1]. In this study we 
have identified the nature of VEGF-A producing cells 
in sections of human reactive lymph nodes and tonsils. 
Specifically, double-immunohistochemistry shows that 
CD1c+ mDCs and interdigitating DCs represent a major 
source of VEGF-A in inflamed secondary lymphoid 
organs. Interdigitating DCs originate from Langerhans 
cells migrated via lymphatics. On the other hand, 
CD1c+ mDCs, located in the extranodular compartments 
surrounding HEVs, likely migrated from the blood. 
Because of their different nodal location, each of these 
cell types may play a specific role in the neo-angiogenesis 
process of lymphatics sinuses and HEVs, respectively.
Our results from in vitro studies show that DCs can 
readily produce VEGF-A in response to a large variety 
of PAMPs and DAMPs if PGE
2
 is present in the local 
microenvironment, demonstrating a non-redundant role 
for PGE
2
 in VEGF-A production by DCs. This PGE
2
 may 
either be endogenously produced by DCs, or provided 
together with the stimuli (outlined in Figure 6). Despite 
PGE
2
 concentrations shown in Figure 2A and 2B were 
higher than those released by DCs (Figure 3A), similar 
results were obtained with PGE
2
 concentrations resembling 
those autocrinally released (0.01 µM, not shown). The 
presence of CD11c/VEGF-A/PGE
2 
positive cells in tissue 
sections supports the existence of an autocrine mechanism 
in vivo. In addition PGE
2
, which is abundantly produced 
by many cell types in inflamed tissues and lymph nodes 
[25, 11, 12], may also act paracrinally to support VEGF-A 
production in the presence of PAMPs or DAMPs unable 
to induce PGE
2
 in DCs. PGE
2
 regulates several DC 
functions including migration, edema formation and T 
cell polarization [25] [28] [29] [30]. This report further 
strengthen the importance of PGE
2
 in DC biology showing 
the crucial role of this prostenoid for VEGF-A production. 
Furthermore, this study provides an additional mechanism 
by which COX-2 may promote inflammatory and/or tumor 
angiogenesis [31]. 
From a mechanistic point of view, our data propose 
CREB phosphorylation as the crucial contribution of PGE
2
 
to VEGF-A secretion, while TLRs are responsible for the 
activation of HIF-1α and STAT3. The mechanisms of HIF-
1α and STAT3 activation by TLRs remain unexplained. 
It was previously described in cancer cell lines that pro-
inflammatory cytokines and TLR3-4 ligands induce HIF-
1α accumulation under normoxic conditions [32-36], an 
effect often correlated with COX-2 activation. However, 
in DCs, HIF-1α accumulation does not depend on COX-2 
activation since it is detected also after the stimulation with 
Poly I:C. In addition, we found that COX inhibition could 
not prevent HIF-1α accumulation in LPS-stimulated DCs 
(V.S., unpublished results). Based on these observations, 
we hypothesize that HIF-1α accumulation may depend 
on a direct effect of TLR signalling, possibly mediated 
by ROS that were described to inhibit PHD enzymes and 
stabilize HIF-1α protein [37]. The mechanisms of STAT3 
activation are even more puzzling. A good candidate 
would be an autocrine loop involving IL-6, which is 
induced by several TLRs and is a well known VEGF-A 
inducer [5]. However, an IL-6R-blocking antibody did not 
inhibit the release of VEGF-A (V.S., unpublished results) 
in our system. Also, the production of VEGF-A was not 
affected by antibodies blocking the receptors for IL-10 
and IFN-I (V.S., unpublished results), thus suggesting 
the involvement of a different mediator which remains 
elusive. Further work is granted to better characterize the 
mechanisms responsible for HIF-1α and STAT3 activation 
in TLR-stimulated DCs.
The conclusion that, in DCs, three transcription 
factors (namely HIF-1α, STAT3 and CREB) are required 
to induce VEGF-A transcription (outlined in Figure 6) 
is supported by experiments performed with specific 
inhibitors and by the observation that agonists which fail 
to induce the activation of these transcription factors also 
fail to induce VEGF-A transcription, unless combined with 
exogenous PGE
2
. This is the case for TLR3 activation, 
which accumulates HIF-1α and phospho-STAT3 but 
fails to induce CREB phosphorylation. Similarly, CoCl
2
, 
which accumulates HIF-1α and phospho-STAT3, induces 
VEGF-A only when combined with CREB-activating 
drug cpt-cAMP. These latter findings suggest that the 
presence of three transcription factors is crucial not only 
in pro-inflammatory, but also in hypoxic conditions. In the 
past, seminal work postulated the need for a multiprotein 
complex, including HIF-1α and an “adjacent transcription 
factor” to regulate the transcription of hypoxic genes 
[38, 39]. In line with this, it was recently proposed that 
STAT3 may cooperatively activate HIF-1α-target genes 
by increasing the recruitment of the coactivators CBP and 
p300 [7, 27, 40]. Our results further support these findings 
showing the need for three transcription factors for the 
inflammatory production of VEGF-A. 
An unresolved question is whether HIF-1α, STAT3 
and CREB activate VEGF-A transcription dependently 
or independently from each other, i.e. if they form a 
protein complex (or enhanceosome) in human DCs. Even 
in the absence of direct evidence from co-occupancy 
experiments, several data strongly support this hypothesis. 
First, the three transcription factors can be detected on the 
same promoter region, encompassing functional HIF and 
STAT3 sites less than 150 bp apart one from the other. This 
region is devoid of a characterized CRE site, but a nearby 
(less than 200 bp) functional AP-1 site [5] may bind 
CREB because of core consensus sequence similarities 
[41]. Alternatively, the binding of CREB to the VEGF-A 
promoter may be indirect, i.e. mediated by coactivators 
as previously proposed [42]. Finally, we show that the 
inhibition of each single transcription factor completely 
flattens the secretion of VEGF-A. This suggests the 
existence of a protein complex encompassing the three 
transcription factors, which cannot be assembled in the 
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lack of one member, thus failing to recruit co-activators 
and to activate transcription. 
In conclusion, this study shows that, in inflammatory 
conditions, human DCs can produce conspicuous amounts 
of VEGF-A, in vitro and in vivo. Our data also show 
that in inflamed lymph nodes DCs represent one of the 
few cell types contributing VEGF-A production. This 
finding makes DCs a new potential therapeutic target 
to limit lymph node vascular expansion in chronic- and 
tumor-associated inflammation. Furthermore, the formal 
definition of the enhanceosome composition might allow 
to specifically target DC-derived VEGF-A preserving the 
physiological angiogenesis as well as the global activation 
of transcription factors mastering key physiological 
processes. Altogether, this study further expands our 
knowledge on the plasticity of DCs and on their complex 
role in the regulation of innate immune responses.
MAterIAls And Methods
Immunohistochemistry
Formalin-fixed paraffin-embedded human tissues 
were retrieved from the archive of the Department of 
Pathology (Spedali Civili di Brescia, Brescia, Italy). 
Anti-VEGF-A polyclonal antibody (1:500, Thermo 
Scientific, CA) was applied to 4-μm thick tissue sections, 
after appropriate antigen retrieval (microwave oven 3x5 
minutes 750W in EDTA buffer, pH 8.0); the reaction was 
revealed using Novolink Polymer (Leica Microsystems, 
UK) followed by DAB. Anti-PGE
2
 (polyclonal 
Rabbit, 1:700 over night, Biorbyt) was revealed using 
DakoEnvision+System-HRP Labelled Polymer Anti-
Rabbit and DAB after antigen retrieval (thermostatic 
bath, TRIS-EDTA buffer, pH 9.0). Isotype control stains 
for both VEGF-A and PGE
2
 were performed and gave 
no reactivity. Characterization of VEGF-A positive cells 
was performed by double immunohistochemistry using 
antibodies to the following antigens: CD31 (mouse IgG1, 
clone 1A10, 1:50, Leica Microsystems), CD1a (mouse, 
clone 010, 1:50, Dako, Denmark), CD3 (rabbit, clone SP7, 
1:100, Thermo Scientific), CD11c (mouse, clone 5D11, 
1:50, Leica Microsystems), CD20 (mouse, clone L26, 
1:250, Dako), CD163 (mouse, clone 10D6, 1:50, Thermo 
Scientific), CD207/Langerin (mouse, clone 12D6, 1:200, 
Vector Laboratories, CA) and CD303/BDCA2 (mouse, 
clone 124B3.13, 1:75, Dendritics, France) and M-DC8 
(mouse, clone DD1, 1:70, kindly provided by K. Schäkel) 
and visualized using Mach 4 MR-AP (Biocare Medical, 
CA), followed by Ferangi Blue (Biocare Medical) as 
chromogen. Immunostained sections were photographed 
using the DP-70 Olympus digital camera mounted on the 
Olympus BX60 microscope.
cell preparation and culture
Buffy coats were obtained through the courtesy of the 
Centro Trasfusionale, Spedali Civili, Brescia. Monocytes 
were purified from peripheral blood mononuclear cells 
(PBMC) by immunomagnetic separation using anti 
CD14-conjugated magnetic microbeads (Miltenyi Biotec, 
Bergisch Gladbach, Germany). Monocyte-derived DCs 
were differentiated as previously described [43]. Briefly, 
monocytes cultured for 6 days in tissue culture plates 
in RPMI 1640 (Gibco, Invitrogen, Carlsbad, CA, USA) 
supplemented with 10% heat-inactivated fetal calf serum 
(FCS, Lonza Group, Switzerland), 2 mM L-glutamine, 
antibiotics (Gibco) (completed RPMI medium), 50 ng/ml 
GM-CSF and 20 ng/ml IL-4 (ProSpec Technogene, Israel). 
To generate Langerhans cells, monocytes were cultured 
for 6 days in completed RPMI medium in the presence of 
50 ng/ml GM-CSF, 10 ng/ml IL-4 and 10 ng/ml TGF-β 
(Peprotech, London, U.K). Langerhans cell differentiation 
was controlled by monitoring Langerin and E-Cadherin 
expression. Myeloid DCs (mDCs) and plasmacytoid 
DCs (pDCs) were isolated using the corresponding Cell 
Isolation Kit (Miltenyi Biotec). pDCs were cultured in 
completed RPMI medium and 20 ng/ml IL-3 (ProSpec). 
Necrotic cells were obtained via four cycles of freezing 
and thawing. Hypoxia (1% O
2
, 37°C) was performed in 
the InVivo
2
 400 hypoxic workstation (Ruskinn-Biotrace, 
UK).
cell stimulation
DCs (2x106 cells/ml) were stimulated with the 
following agonists: 100 ng/ml PAM
3
CSK
4
, ligand for 
TLR1/2; 100 ng/ml FSL-1, ligand for TLR2/6; 25 µg/ml 
Poly I:C, ligand for TLR3; 100 ng/ml flagellin, ligand for 
TLR5 (Bacillus subtilis); 5 µg/ml imiquimod, ligand for 
TLR7; 5 µg/ml R848, ligand for TLR7 and TLR8 (from 
now on: TLR7-8); 6 µg/ml CpG ODN 2216, ligand for 
TLR9 (all from Invivogen, San Diego, California, USA); 
100 ng/ml LPS, ligand for TLR4 (Escherichia coli 055:B5; 
Sigma-Aldrich, St. Louis, MO); 10 µg/ml β-glucan from 
baker’s yeast (Saccharomyces cervisiae) or Curdlan (from 
Alcaligenes faecalis), both ligands for dectin-1 (both from 
Sigma-Aldrich); 20 ng/ml IL-1β and TNF-α (Peprotech). 
Heat-killed Staphylococcus aureus, Escherichia coli and 
Candida albicans was purchased from Invivogen. Where 
indicated, 10 µM PGE
2
, 25 µM cpt-cAMP, 400 µM Cobalt 
Chloride (CoCl
2
) were added (all from Sigma-Aldrich). 
DRB (an inhibitor of RNApolII), Chetomin (HIF-1α 
inhibitor), NSC 74859 (STAT3 inhibitor) were from 
Sigma-Aldrich; indomethacin (a non selective COX-
1 and COX-2 inhibitor), U0126 (a MEK1/2 inhibitor), 
PD98059 (an ERK1/2 inhibitor), SB203580 (a p38 
MAPK inhibitor), JNK Inhibitor II (a JNK inhibitor), 
BAY11-7082 (a NF-κB inhibitor), CBP-CREB interaction 
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inhibitor were from Calbiochem (San Diego, CA); H89 
(a PKA inhibitor), AH 6809 (an EP
2
 antagonist), GW 
627368X (an EP
4
 antagonist), Butaprost (EP
2
 agonist), 
Misoprostol (EP
4
,EP
3
 > EP
2
 agonist) and Sulprostone (EP
1
/
EP
3
 agonist) were from Cayman Chemical (Michigan, 
USA). AACOF3 (Arachidonyltrifluormethyl ketone, a 
cPLA
2
 inhibitor) was purchased from Biomol (Enzo Life 
Sciences, Farmingdale).
chromatin immunoprecipitation
After stimulation, cells were fixed by adding 
directly to the medium 36% formaldehyde (Sigma-
Aldrich) to a final concentration of 1% for 7 minutes. 
The cross-linking reaction was stopped by adding Tris 
to a final concentration of 125 mM. After 10 minutes, 
ice-cold PBS was added and plates were transferred on 
ice, washed extensively with PBS, and scraped. After 
centrifugation, cells were lysed for 5 minutes in L1 buffer 
(50 mM Tris pH 8.0, 2 mM EDTA, 0.1% Nonidet P-40 
and 10% glycerol) supplemented with inhibitors (1 mM 
Na3VO4, 2 mM DTT, 1 mM NaF, 1 mM PMSF and 
Protease Inhibitors Cocktail, all reagents were purchased 
from Sigma-Aldrich). Nuclei were pelleted at 3000 rpm 
in a cold microfuge and resuspended in L2 buffer (50 mM 
Tris pH 8.0, 1% SDS and 5 mM EDTA) plus inhibitors. 
Chromatin was sheared by sonication (3 x 20 s at 50% 
of the maximum potency), centrifuged to pellet debris, 
and diluted 10 times in dilution buffer (50 mM Tris 
pH 8.0, 0.5% Nonidet P-40, 200 mM NaCl and 5 mM 
EDTA). Extracts were precleared for 3 hours with a 50% 
suspension of salmon sperm-saturated protein A (ss protein 
A). Immunoprecipitations were carried out overnight at 
4°C using 3 µg of the following antibodies raised against 
RNApolII (N-20 sc-899, Santa Cruz Biotechnology, CA, 
USA), HIF-1α (NB 10134, Novus Biologicals, CO, USA), 
STAT3 (C-20 sc-482, Santa Cruz Biotechnology) [44], 
pCREBSer133 (Cat. 17-10131, Millipore; USA). Immune 
complexes were collected with protein A and washed three 
times (10 minutes each) with high salt buffer (washing 
buffer: 20 mM Tris pH 8.0, 0.1% SDS, 1% Nonidet P-40, 
2 mM EDTA and 500 mM NaCl supplemented with 1mM 
PMSF) and three times with low salt buffer (1x Tris/
EDTA [TE]). Immune complexes were extracted in 1x TE 
containing 2% SDS, and protein-DNA cross-links were 
reverted by heating at 65°C overnight. DNA was then 
extracted with the QIAquick PCR purification kit (Qiagen, 
Crawley, UK) and 1/20 of the immunoprecipitated 
DNA was used in each quantitative PCR reaction. 
Sequences of promoter-specific primers used were the 
following: VEGF-A -884 to detect transcription factor 
binding (forward: 5’-TGATGTCTGCAGGCCAGAT-3’, 
reverse: 5’-CCACAGTGTGTCCCTCTGAC-3’) 
and VEGF-A -291 to detect RNApolII recruitment 
(forward: 5’-GTCCGCACGTAACCTCACTT-3’, 
reverse: 5’-CAGCCTGAAAATTACCCATCC-3’). In all 
experiments, 10% of the input chromatin was removed 
prior to addition of the antibodies and used to normalize 
the amount of immunoprecipitated DNA (specified in the 
text as “input” DNA). 
elIsA
DCs were incubated for 24 hours with the indicated 
treatments. Cell-free supernatants were harvested and 
VEGF-A and IL-6 production was measured by ELISA 
assay (R&D Systems, Minneapolis, MN, USA). PGE2 
production was assessed by EIA kit (Cayman Chemical).
SDS-PAGE and western blot
Following the designated treatments, DCs were 
washed twice with PBS and lysed in L1 buffer with 
inhibitors to separate cytoplasmic proteins. Nuclear pellets 
were washed twice with L1 buffer with inhibitors and then 
lysed in Nonidet P-40 Lysis buffer (50 mM Tris-HCl, pH 
8.0; 250 mM NaCl; 1 mM EDTA; 0.1% Nonidet P-40 and 
10% glycerol) with inhibitors. Equal amounts of extracts 
were analyzed through 8-12% SDS-PAGE followed by 
Western blotting with antibodies against phospho-CREB 
(Cat. 9198, Cell Signalling), phospho-STAT3 (Cat. 9131, 
Cell Signalling), HIF-1α (Cat. 610959, BD Bioscience), 
and Lamin B (C-20 sc-6216, Santa Cruz Biotechnology). 
Protein bands were detected with SuperSignal West Pico 
Chemiluminescent Substrate (Pierce, Rockford, USA). 
Densitometric analysis was performed using ImageJ 
(version 1.48) software package from National Institutes 
of Health. Immunoblots were scanned as JPEG images and 
the areas under the curves were measured for each band 
and quantified. Data were normalized based on Lamin B 
content.
real-time Pcr
RNA was extracted using TRIzol reagent 
(Invitrogen) according to the manufacturer’s 
instructions. After RNA purification, samples were 
treated with DNAse to remove contaminating genomic 
DNA (DNaseI Amplification grade, Invitrogen). 
Reverse transcription was performed using random 
hexamers and MMLV RT (Invitrogen). Gene-specific 
primers used were as follows: hVEGF-A (forward: 
5’-AGTGTGTGCCCACTGAGGA-3’, reverse: 
5’-GGTGAGGTTTGATCCGCATA-3’), hHPRT (forward: 
5’-CCAGTAACAGGGGACATAAA-3’, reverse: 
5’-CACAATCAAGACATTCTTTCCAGT-3’). The 
SsoAdvanced Universal SYBR Green Supermix (Bio-Rad 
Laboratories Inc., Hercules, CA, USA) for quantitative 
real-time PCR was used according to the manufacturer’s 
instructions. Reactions were run in triplicate on a StepOne 
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Plus Real-Time PCR System (Applied Biosystems) and the 
generated products analyzed by the StepOne Plus Software 
(Version 2.3, Applied Biosystems). Gene expression was 
normalized based on HPRT mRNA content. 
FAcs analysis
DCs were treated with 100 ng/ml LPS for 24 hours. 
At the end of the incubation, cells were permeabilized 
using the Cytofix/Cytoperm kit (BD Bioscience, San 
Diego, CA) and stained with antibodies against EP
2
 and 
EP
4
 receptors (Cayman Chemical) or with the isotype 
control for 30 minutes, washed with PBS (Gibco) and 
incubated with anti-rabbit Alexa-488 (Invitrogen). 
Samples were read on a PAS (Partec GmbH, Muenster, 
Germany) and analysed with FlowJo (Tree Star Inc, 
Ashland, USA). To assess cell viability, DCs were stained 
with Propidium Iodide (Invitrogen).
statistical analysis
Statistical significance among the experimental 
groups was determined using paired Student’s t test or one-
way ANOVA with Dunnet’s post hoc test as appropriated 
(GraphPad Prism version 4.00 for Windows, GraphPad 
Software).
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